|
Bristol-Myers
Squibb buys DuPont Pharmaceuticals Company
Bristol-Myers Squibb has announced the agreement to buy DuPont Pharmaceuticals
Company. This will add efavirenz to the BMS HIV portfolio with the
potential for a once-daily treatment option when combined with ddI
and d4T.
posted
6/22/2001
|